CA2834400A1 - Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease - Google Patents

Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease Download PDF

Info

Publication number
CA2834400A1
CA2834400A1 CA2834400A CA2834400A CA2834400A1 CA 2834400 A1 CA2834400 A1 CA 2834400A1 CA 2834400 A CA2834400 A CA 2834400A CA 2834400 A CA2834400 A CA 2834400A CA 2834400 A1 CA2834400 A1 CA 2834400A1
Authority
CA
Canada
Prior art keywords
difficile
lactoferrin
treatment
disease
fecal sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2834400A
Other languages
English (en)
French (fr)
Inventor
James Hunter Boone
David M. Lyerly
Tracy D. Wilkins
Robert J. Carman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Techlab Inc
Original Assignee
Techlab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techlab Inc filed Critical Techlab Inc
Publication of CA2834400A1 publication Critical patent/CA2834400A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2834400A 2011-04-29 2012-04-27 Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease Abandoned CA2834400A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161480616P 2011-04-29 2011-04-29
US61/480,616 2011-04-29
US13/457,049 2012-04-26
US13/457,049 US20120276059A1 (en) 2011-04-29 2012-04-26 Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease
US13/457,064 US20120276060A1 (en) 2011-04-29 2012-04-26 Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease
US13/457,064 2012-04-26
PCT/US2012/035495 WO2012149351A1 (en) 2011-04-29 2012-04-27 Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease

Publications (1)

Publication Number Publication Date
CA2834400A1 true CA2834400A1 (en) 2012-11-01

Family

ID=47068058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2834400A Abandoned CA2834400A1 (en) 2011-04-29 2012-04-27 Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease

Country Status (5)

Country Link
US (3) US20120276059A1 (https=)
EP (1) EP2705154A4 (https=)
JP (1) JP6077524B2 (https=)
CA (1) CA2834400A1 (https=)
WO (1) WO2012149351A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
US10295535B2 (en) * 2011-04-29 2019-05-21 Techlab, Inc. Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with clostridium difficile disease and differentiating carrier state from active disease
US20120276059A1 (en) 2011-04-29 2012-11-01 Techlab, Inc. Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease
US9133527B2 (en) * 2012-05-11 2015-09-15 Techlab, Inc. Cell wall protein CwpV (CD0514) as a diagnostic marker for Clostridium difficile ribotype 027
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102099503B1 (ko) 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
ES2889902T3 (es) 2015-06-09 2022-01-14 Rebiotix Inc Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM)
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
EA034885B1 (ru) * 2015-07-03 2020-04-02 Астеллас Фарма Юэроп Лтд. Новая схема лечения тиакумициновым соединением
WO2017100420A1 (en) * 2015-12-08 2017-06-15 Mayo Foundation For Medical Education And Research Biomarkers for predicting clostridium difficile infection treatment outcome
CN109682979A (zh) * 2019-01-30 2019-04-26 珠海市银科医学工程股份有限公司 一种钙卫蛋白联合乳铁蛋白抗原检测试纸条及其制备方法
US11139063B1 (en) 2020-12-29 2021-10-05 Kpn Innovations, Llc. Systems and methods for generating a microbiome balance plan for prevention of bacterial infection
US12322493B2 (en) 2020-12-29 2025-06-03 Kpn Innovations, Llc. Systems and methods for generating a lifestyle-based disease prevention plan
US12322491B2 (en) 2021-03-01 2025-06-03 Kpn Innovations, Llc. System and method for generating a geographically linked nourishment program
WO2022206585A1 (zh) * 2021-03-29 2022-10-06 广州市妇女儿童医疗中心 诊断先天性巨结肠的抗体标志物及其应用
CN114252596A (zh) * 2021-12-01 2022-03-29 珠海科域生物工程股份有限公司 一种粪便乳铁蛋白检测试剂盒及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965375A (en) 1997-04-04 1999-10-12 Biosite Diagnostics Diagnostic tests and kits for Clostridium difficile
JP2000155121A (ja) * 1998-11-18 2000-06-06 Nitto Denko Corp 免疫学的検査法
AU2002902A (en) 2000-11-14 2002-05-27 Techlab Inc Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrinas a marker
PL1824991T3 (pl) 2004-11-24 2016-08-31 Techlab Inc Urządzenie oraz sposób do wykrywania analitów
BRPI0906060A2 (pt) 2008-02-28 2015-12-01 3M Innovative Properties Co anticorpos isolados, métodos de preparo de um anticorpo anti-clostridium difficile, composição e método para a detecção da presença de um esporo de clostridium difficile em uma amostra
US20120276059A1 (en) 2011-04-29 2012-11-01 Techlab, Inc. Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease

Also Published As

Publication number Publication date
EP2705154A4 (en) 2014-11-12
US20120276059A1 (en) 2012-11-01
JP6077524B2 (ja) 2017-02-08
JP2014519018A (ja) 2014-08-07
US10295536B2 (en) 2019-05-21
US20140219966A1 (en) 2014-08-07
EP2705154A1 (en) 2014-03-12
US20120276060A1 (en) 2012-11-01
WO2012149351A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
US10295536B2 (en) Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with Clostridium difficile disease
Rubenstein et al. Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms
Sýkora et al. Evaluation of faecal calprotectin as a valuable non‐invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis
Battat et al. Serum concentrations of 7α-hydroxy-4-cholesten-3-one are associated with bile acid diarrhea in patients with Crohn’s disease
Neufeld et al. Galactose-deficient IgA1 in skin and serum from patients with skin-limited and systemic IgA vasculitis
Odaka et al. Evaluation of TheHelicobacter PyloriStool Antigen Test for Monitoring Eradication Therapy
US10295535B2 (en) Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with clostridium difficile disease and differentiating carrier state from active disease
Usacheva et al. Host response to Clostridium difficile infection: Diagnostics and detection
EP1444519A2 (en) Method and apparatus for distinguishing crohn's disease from ulcerative colitis and other gastrointestinal diseases by detecting the presence of fecal antibodies to saccharomyces cerevisiae
Sorour et al. Evaluation of hepatocyte growth factor as a local acute phase response marker in the bowel: the clinical impact of a rapid diagnostic test for immediate identification of acute bowel inflammation
NZ701004B2 (en) Clostridium difficile dehydrogenase and toxin as a biomarker
Burns et al. The novel duodenal isolate streptococcus salivarius AGIRA0003 promotes barrier dysfunction and IgG responses in functional dyspepsia
Nakamura et al. Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study
Lu et al. The clinical applications and accuracy of 2 rapid near-patient tests in detecting Helicobacter pylori infection
Bayoumy et al. Antivinculin antibodies as a marker of irritable bowel syndrome–diarrhea in Egyptian patients
CN103123355B (zh) 一种用于前列腺癌骨转移诊断的试剂盒及其使用方法
Ali et al. The effect of typhoid fever on cytokines (interleukin-6 and 8) and C-reactive protein concentration
Zhu et al. Helicobacter pylori antigen and its IgG, IgA-type specific immunocomplexes in sera from patients with Helicobacter pylori infection
Sun et al. Metagenomic next-generation sequencing enhances the diagnosis of Q fever: A retrospective observational study
Lorenz et al. Interferon-gamma release assay in the ascites: Early hint for diagnosis of abdominal tuberculosis
Zhang et al. Confusion in Breath Test for Diagnosing Bacterial Overgrowth in the Small Intestine
Gazim et al. Níveis de calprotectina fecal na uveite anterior aguda em pacientes com espondiloartrites
Jemilohun et al. Management of Helicobacter pylori infection
US20210405048A1 (en) Diagnosing Sepsis or Bacteremia by Detecting Peptidoglycan Associated Lipoprotein (PAL) in Urine
Yang et al. P020 Serum Ustekinumab and Anti-Ustekinumab Antibody: Analysis of Over 2000 Patient Results Using Lab Developed Electrochemiluminescent Immunoassays (ECLIA)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170320

FZDE Discontinued

Effective date: 20230228